phase readout
saveNCT05378763: A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
SUSPENDEDupdated 22h ago
community read0 votes
Sponsor: Spectrum Pharmaceuticals, Inc. Phase: PHASE3. Conditions: NSCLC
view source ↗
comments(0)
5-min edit window · permanent after that